Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
142 patient apilimod early treatment RCT: 199% higher mortality (p=1), 100% higher combined mortality/hospitalization (p=1), and 109% worse recovery (p=0.43).
RCT 142 COVID-19 patients showing no significant differences with apilimod treatment.
Apr 2021, NCT04446377, https://clinicaltrials.gov/study/NCT04446377, https://c19p.org/young3
